Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Interventions to improve oral vaccine performance: a systematic review and meta-analysis.

Church JA, Parker EP, Kirkpatrick BD, Grassly NC, Prendergast AJ.

Lancet Infect Dis. 2019 Feb;19(2):203-214. doi: 10.1016/S1473-3099(18)30602-9. Epub 2019 Jan 30.

2.

Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh.

Emperador DM, Velasquez DE, Estivariz CF, Lopman B, Jiang B, Parashar U, Anand A, Zaman K.

Clin Infect Dis. 2016 Jan 15;62(2):150-6. doi: 10.1093/cid/civ807. Epub 2015 Sep 8.

3.

Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.

O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA; Chilean IPV/bOPV study group.

Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Erratum in: Lancet Infect Dis. 2015 Oct;15(10):1130.

PMID:
26318714
4.

Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS.

Lancet Infect Dis. 2016 Mar;16(3):321-30. doi: 10.1016/S1473-3099(15)00488-0. Epub 2015 Dec 21.

PMID:
26719058
5.

Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.

Mir F, Quadri F, Mach O, Ahmed I, Bhatti Z, Khan A, Rehman NU, Durry E, Salama M, Oberste SM, Weldon WC, Sutter RW, Zaidi AK.

Lancet Infect Dis. 2015 Aug;15(8):889-97. doi: 10.1016/S1473-3099(15)00093-6. Epub 2015 Jun 17.

6.

Key issues in the persistence of poliomyelitis in Nigeria: a case-control study.

Mangal TD, Aylward RB, Mwanza M, Gasasira A, Abanida E, Pate MA, Grassly NC.

Lancet Glob Health. 2014 Feb;2(2):e90-7. doi: 10.1016/S2214-109X(13)70168-2. Epub 2014 Jan 23.

7.

Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.

Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, Borate BR, Gast C, Clemens R, Orenstein W, O'Ryan G M, Jimeno J, Clemens SA, Ward J, Rüttimann R; Latin American IPV001BMG Study Group.

Lancet. 2016 Jul 9;388(10040):158-69. doi: 10.1016/S0140-6736(16)00703-0. Epub 2016 May 19. Erratum in: Lancet. 2016 Jul 9;388(10040):e2.

PMID:
27212429
8.

Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis.

Parker EP, Kampmann B, Kang G, Grassly NC.

J Infect Dis. 2014 Sep 15;210(6):853-64. doi: 10.1093/infdis/jiu182. Epub 2014 Mar 31. Review.

9.

Interventions for improving coverage of childhood immunisation in low- and middle-income countries.

Oyo-Ita A, Wiysonge CS, Oringanje C, Nwachukwu CE, Oduwole O, Meremikwu MM.

Cochrane Database Syst Rev. 2016 Jul 10;7:CD008145. doi: 10.1002/14651858.CD008145.pub3. Review.

10.

The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants.

Grassly NC, Praharaj I, Babji S, Kaliappan SP, Giri S, Venugopal S, Parker EP, Abraham A, Muliyil J, Doss S, Raman U, Liu J, Peter JV, Paranjape M, Jeyapaul S, Balakumar S, Ravikumar J, Srinivasan R, Bahl S, Iturriza-Gómara M, Uhlig HH, Houpt ER, John J, Kang G.

Lancet Infect Dis. 2016 Aug;16(8):905-14. doi: 10.1016/S1473-3099(16)30023-8. Epub 2016 May 4.

11.

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.

Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande J, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB.

Lancet. 2010 Nov 13;376(9753):1682-8. doi: 10.1016/S0140-6736(10)61230-5. Epub 2010 Oct 25.

PMID:
20980048
12.

Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.

Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB.

Lancet. 2015 Dec 12;386(10011):2413-21. doi: 10.1016/S0140-6736(15)00237-8. Epub 2015 Sep 18. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.

PMID:
26388534
13.

Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.

Estívariz CF, Anand A, Gary HE Jr, Rahman M, Islam J, Bari TI, Wassilak SG, Chu SY, Weldon WC, Pallansch MA, Heffelfinger JD, Luby SP, Zaman K.

Lancet Infect Dis. 2015 Aug;15(8):898-904. doi: 10.1016/S1473-3099(15)00094-8. Epub 2015 Jun 17.

PMID:
26093980
14.

Community engagement and integrated health and polio immunisation campaigns in conflict-affected areas of Pakistan: a cluster randomised controlled trial.

Habib MA, Soofi S, Cousens S, Anwar S, Haque NU, Ahmed I, Ali N, Tahir R, Bhutta ZA.

Lancet Glob Health. 2017 Jun;5(6):e593-e603. doi: 10.1016/S2214-109X(17)30184-5. Erratum in: Lancet Glob Health. 2017 Aug;5(8):e758. Lancet Glob Health. 2017 Sep;5(9):e873.

15.

Impact of enterovirus and other enteric pathogens on oral polio and rotavirus vaccine performance in Bangladeshi infants.

Taniuchi M, Platts-Mills JA, Begum S, Uddin MJ, Sobuz SU, Liu J, Kirkpatrick BD, Colgate ER, Carmolli MP, Dickson DM, Nayak U, Haque R, Petri WA Jr, Houpt ER.

Vaccine. 2016 Jun 8;34(27):3068-3075. doi: 10.1016/j.vaccine.2016.04.080. Epub 2016 May 3.

16.

Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines.

Patel M, Steele AD, Parashar UD.

Vaccine. 2012 Apr 27;30 Suppl 1:A30-5. doi: 10.1016/j.vaccine.2011.11.093. Review.

PMID:
22520134
17.

The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis.

O'Reilly KM, Durry E, ul Islam O, Quddus A, Abid N, Mir TP, Tangermann RH, Aylward RB, Grassly NC.

Lancet. 2012 Aug 4;380(9840):491-8. doi: 10.1016/S0140-6736(12)60648-5. Epub 2012 Jul 4.

18.

Oral and inactivated poliovirus vaccines in the newborn: a review.

Mateen FJ, Shinohara RT, Sutter RW.

Vaccine. 2013 May 17;31(21):2517-24. doi: 10.1016/j.vaccine.2012.06.020. Epub 2012 Jun 20. Review.

19.

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Muliyil J, Abraham A, Grassly NC, Kang G.

Lancet. 2014 Oct 25;384(9953):1505-12. doi: 10.1016/S0140-6736(14)60934-X. Epub 2014 Jul 10.

PMID:
25018120
20.

Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.

Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, Cultrera R, Villari P, Ricciardi W, Ioannidis JPA, Contopoulos-Ioannidis DG.

Lancet Infect Dis. 2018 Apr;18(4):461-472. doi: 10.1016/S1473-3099(18)30048-3. Epub 2018 Jan 19. Erratum in: Lancet Infect Dis. 2018 Mar 22;:.

PMID:
29371070

Supplemental Content

Support Center